
Sanofi reveals promising data for FDA-delayed diabetes drug
pharmafile | September 14, 2016 | News story | Research and Development, Sales and Marketing |Â Â FDA, Lantus, Sanofi, iglarlixiÂ
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could be more effective than its Lantus blockbuster.
The FDA delayed its review of the drug in August, citing a lack of adequate data.
IGlarLixi combines the active ingredients in Lantus (insulin glargine) with Sanofi’s GLP-1 agonist Lyxumia (lixisenatide). According to the new findings, the combination drug proved more effective in controlling mealtime blood glucose than Lantus, helping more type 2 diabetes patients reach post-prandial glucose targets.
“Controlling mealtime blood sugar is an important element of maintaining overall blood sugar control, which plays a role in helping patients treat their diabetes,” commented Josep Vidal of the Hospital Clinic of Barcelona, who presented the results at the European Association for the Study of Diabetes (EASD) meeting in Munich.
Prior results from the LixiLan-L trial have shown that the combination is more effective than Lantus in controlling haemoglobin A1c levels, a biomarker for glucose control over time.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …






